Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D. Castro E, et al. J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9. J Clin Oncol. 2019. PMID: 30625039
Inherited mutations in DNA repair genes and cancer risk.
Romero-Laorden N, Castro E. Romero-Laorden N, et al. Curr Probl Cancer. 2017 Jul-Aug;41(4):251-264. doi: 10.1016/j.currproblcancer.2017.02.009. Epub 2017 Mar 22. Curr Probl Cancer. 2017. PMID: 28454847 Review.
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Romero-Laorden N, Lozano R, Jayaram A, López-Campos F, Saez MI, Montesa A, Gutierrez-Pecharoman A, Villatoro R, Herrera B, Correa R, Rosero A, Pacheco MI, Garcés T, Cendón Y, Nombela MP, Van de Poll F, Grau G, Rivera L, López PP, Cruz JJ, Lorente D, Attard G, Castro E, Olmos D. Romero-Laorden N, et al. Br J Cancer. 2018 Oct;119(9):1052-1059. doi: 10.1038/s41416-018-0123-9. Epub 2018 Aug 21. Br J Cancer. 2018. PMID: 30131546 Free PMC article. Clinical Trial.
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Conteduca V, et al. Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26. Eur Urol. 2019. PMID: 30773204 Free PMC article.
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U. Conteduca V, et al. Eur J Cancer. 2019 Jul;116:158-168. doi: 10.1016/j.ejca.2019.05.007. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31200322
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S, Caffo O, Zivi A, Pezaro CJ, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez MI, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS. Rescigno P, et al. Eur Urol Oncol. 2020 Apr;3(2):176-182. doi: 10.1016/j.euo.2019.06.008. Epub 2019 Jul 13. Eur Urol Oncol. 2020. PMID: 31307958 Free article.
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.
Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodríguez-Vida A, Lainez N, Villatoro R, Llácer C, Cattrini C, Hernández A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, López-Campos F, Gonzalez B, Méndez-Vidal MJ, Medina A, Piulats JM, Olmos D; PROREPAIR-B Study Investigators. Lorente D, et al. Eur Urol. 2020 Jun;77(6):763-766. doi: 10.1016/j.eururo.2020.02.025. Epub 2020 Mar 3. Eur Urol. 2020. PMID: 32143923 No abstract available.
Latest progress in molecular biology and treatment in genitourinary tumours.
González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. González-Del-Alba A, et al. Clin Transl Oncol. 2020 Dec;22(12):2175-2195. doi: 10.1007/s12094-020-02373-z. Epub 2020 May 21. Clin Transl Oncol. 2020. PMID: 32440915 Review.
34 results